Research Overview
Retatrutide (LY3437943) is a synthetic triple-receptor agonist engineered to simultaneously activate the GIP receptor, GLP-1 receptor, and glucagon receptor. Unlike single- and dual-agonist compounds, Retatrutide combines three complementary signaling mechanisms within a single peptide structure.
The compound has been widely studied in laboratory settings involving receptor-binding activity, intracellular signaling pathways, metabolic regulation, and energy-homeostasis research. Investigators frequently evaluate Retatrutide because of its unique triagonist design and differentiated signaling profile compared with earlier incretin-based compounds.
Each vial is supplied as a research-grade lyophilized preparation and is intended strictly for in-vitro and preclinical research use. Product-specific analytical documentation may be available upon request.
Mechanism Studied in Research
Research involving Retatrutide frequently focuses on coordinated activation of the GIP receptor, GLP-1 receptor, and glucagon receptor. Published laboratory studies have evaluated its receptor-binding profile, intracellular cAMP signaling, energy-homeostasis pathways, and metabolic regulatory mechanisms.
Researchers commonly investigate how simultaneous activation of these three receptor systems influences downstream signaling networks, cellular energy regulation, receptor sensitivity, and metabolic pathway coordination in controlled experimental models.
Research Applications
Research Applications:
Retatrutide may be evaluated in qualified laboratory settings involving:
Triple-receptor signaling studies
GIP pathway investigations
GLP-1 receptor activity research
Glucagon receptor signaling models
Energy-homeostasis research
Metabolic-regulation frameworks
Cellular signaling pathway studies
Receptor-binding investigations
This product is intended exclusively for laboratory and in-vitro research purposes.
Reconstitution Reference
Reconstitution procedures depend on laboratory protocol, concentration requirements, and intended research application. Researchers should follow validated institutional procedures when preparing lyophilized Retatrutide material.
Use sterile laboratory techniques and appropriate handling procedures. Reconstituted material should be stored according to validated laboratory stability guidelines.
Storage and Handling
Store lyophilized Retatrutide at -20°C and protect from moisture and light. Avoid repeated freeze-thaw cycles.
After reconstitution, handling and storage should follow validated laboratory protocols and institutional research guidelines.
References
[2] Urva S et al. (2022). LY3437943, a novel triple agonist, Phase 1b study in adults with type 2 diabetes. The Lancet.
[3] Rosenstock J et al. (2023). Retatrutide, a GIP/GLP-1/Glucagon receptor agonist, Phase 2 study in type 2 diabetes. The Lancet.
[4] Jastreboff AM et al. (2023). Triple-hormone receptor agonist Retatrutide in adults with obesity. New England Journal of Medicine.